Benzylpenicillin (Penicillin G)
Brand names: Crystapen
Benzylpenicillin (penicillin G) is a parenteral narrow-spectrum beta-lactam given by intravenous or intramuscular injection for serious streptococcal, meningococcal and other susceptible infections, including severe ENT and deep neck-space infections.
Adult dose
Paediatric dose
Dose adjustments
SPC §4.2. For doses of 0.6-1.2 g (1-2 mega units) the dosing interval should be no more frequent than every 8-10 hours. For high doses (e.g. 14.4 g / 24 mega units required for serious infections such as meningitis) adjust by creatinine clearance (mL/min), given as dose (g) / mega units / dosing interval (hours): CrCl 125 — 1.2 or 1.8 g (2 or 3 mega units), interval values given as '2 3'; CrCl 60 — 1.2 g (2 mega units) every 4 hours; CrCl 40 — 0.9 g (1.5 mega units) every 4 hours; CrCl 20 — 0.6 g (1.0 mega unit) every 4 hours; CrCl 10 — 0.6 g (1.0 mega unit) every 6 hours; CrCl nil — 0.3 or 0.6 g (0.5 or 1.0 mega unit), interval values given as '6 8'. CAUTION: the SPC table was flattened to plain text during fetch, so the pairing of the two dose options with the two interval values in the 'CrCl 125' and 'CrCl nil' rows is ambiguous — clinician to confirm against the original SPC table. The dose in that table should be further reduced to 300 mg (0.5 mega units) 8-hourly if advanced liver disease is associated with severe renal failure. If haemodialysis is required, an additional dose of 300 mg (0.5 mega units) should be given 6-hourly during the procedure.
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
SPC §4.2 age bands as stated: children 1 month to 12 years — 100 mg/kg/day in 4 divided doses, not exceeding 4 g/day; infants 1-4 weeks — 75 mg/kg/day in 3 divided doses; newborn infants — 50 mg/kg/day in 2 divided doses. MENINGOCOCCAL DISEASE: children 1 month to 12 years — 180-300 mg/kg/day in 4-6 divided doses, not exceeding 12 g/day; infants 1-4 weeks — 150 mg/kg/day in 3 divided doses; newborn infants — 100 mg/kg/day in 2 divided doses. SUSPECTED MENINGOCOCCAL DISEASE (single dose before transfer to hospital): children 1-9 years 600 mg IV or IM; children under 1 year 300 mg IV or IM. PREMATURE BABIES AND NEONATES: dosing should not be more frequent than every 8 or 12 hours in this age group, since renal clearance is reduced at this age and the mean half-life of benzylpenicillin may be as long as 3 hours; since infants have been found to develop severe local reactions to intramuscular injections, intravenous treatment should preferably be used. Verify all paediatric doses against a children's formulary before prescribing.
Contraindications
- Allergy to penicillins
- Hypersensitivity to any ingredient of the preparation
- Cross-allergy to other beta-lactams such as cephalosporins should be taken into account
Side effects
- Hypersensitivity to penicillin in the form of rashes (all types), fever and serum sickness — common (1-10% of treated patients)
- Jarisch-Herxheimer reaction in patients treated for syphilis or neurosyphilis — very common (>10%)
- Anaphylactic reactions — rare (<0.05% of treated patients); angioedema — frequency not known
- Granulocytopenia (neutropenia), agranulocytosis and leucopenia in patients receiving prolonged high doses — rare (0.01-0.1%)
- Central nervous system toxicity including convulsions, reported with massive doses over 60 g per day and in patients with severe renal impairment — rare
- Interstitial nephritis reported after intravenous benzylpenicillin sodium at doses of more than 12 g per day — rare; and Clostridium difficile diarrhoea
Clinical monograph
How it works
It inhibits bacterial cell-wall synthesis by binding penicillin-binding proteins, and is bactericidal against susceptible Gram-positive cocci such as group A streptococci.
Prescribing in practice
- Contraindicated in patients with previous immediate hypersensitivity to penicillins; check allergy status carefully and have anaphylaxis management available, as serious reactions can occur with parenteral dosing.
- It is acid-labile and not absorbed orally, so it must be given by injection; doses are reduced in significant renal impairment because it is renally cleared.
- Very high parenteral doses contribute a notable sodium and potassium load and have rarely been associated with neurotoxicity (seizures), particularly in renal impairment.
Monitoring
Monitor renal function, electrolytes and clinical response, and observe for hypersensitivity, especially after the first parenteral dose.
Counselling the patient
- Tell staff at once about any rash, swelling, wheeze or faintness during or after the injection.
- Report any previous reaction to penicillin or other antibiotics before treatment.
- Complete the full prescribed course as directed.
Evidence & guidelines
Penicillin G remains a first-line agent for invasive group A streptococcal and meningococcal disease in national antimicrobial and infection guidance.
Reference: NICE NG84; ENT-UK Mastoiditis Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Centor / McIsaac Score for Strep Pharyngitis · Throat
- Centor/McIsaac Score (Pharyngitis) · Throat Infections
- FeverPAIN Score for Strep Throat · Throat
- Jarisch-Herxheimer Reaction Severity Assessment · Treatment Reactions
- PID Severity (CDC Diagnostic Criteria) · Gynaecological Infections
- Gustilo-Anderson Classification (Open Fractures) · Fracture Classification
- Adult Upper Airway Obstruction (Stridor) · DAS 2015 unanticipated difficult airway; RCEM
- Epistaxis Management · ENT-UK / NICE
- Acute Otitis Media · NICE NG91 2018
- Tonsillitis and Sore Throat · NICE NG84 2018
- Benign Paroxysmal Positional Vertigo · NICE CG124 / AAO-HNS Guidelines
- Acute Rhinosinusitis · NICE NG79 2017 / EPOS 2020